NCT06182410View on ClinicalTrials.gov

Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

August 1, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions

Transplant-Associated Thrombotic MicroangiopathyNeuroblastomaHigh-risk NeuroblastomaThrombotic Microangiopathies

Interventions

DRUG

Defibrotide

Given intravenously (IV)

Sponsors

Collaborators (1)

Jazz Pharmaceuticals

All Listed Sponsors

collaborator

Jazz Pharmaceuticals

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT06182410 - Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma | Biotech Hunter | Biotech Hunter